

Yurugi-Kobayashi T, Itoh H, Schroeder T, Nakano A, Narazaki G, Kita F, Yanagi K, Hiraoka-Kanie M, Inoue E, Ara T, Nagasawa T, Just U, Nakao K, Nishikawa S, Yamashita JK.	Adrenomedullin/cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors.	Arterioscler. Thromb. Vasc. Biol.	26	1977-1984	2006
Toyoda T, Tanaka S, Ebihara K, Masuzaki H, Hosoda K, Sato K, Fushiki T, Nakao K, Hayashi T.	Low-intensity contraction activates the α -isoform of 5'-AMP-activated protein kinase in rat skeletal muscle.	Am. J. Physiol. Endocrinol. Metab.	290	E583-E590	2006
Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S, Sakamoto T, Saito Y, Nakao K, Yasue H, Ogawa H.	Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium.	Endocrinology	147	1314-1321	2006
Fujikura J, Hosoda K, Iwakura H, Tomita T, Noguchi M, Masuzaki H, Tanigaki K, Yabe D, Honjo T, Nakao K.	Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas.	Cell Metab.	3	59-65	2006
Miyashita K, Itoh H, Arai H, Suganami T, Sawada N, Fukunaga Y, Sone M, Yamahara K, Yurugi-Kobayashi T, Park K, Oyamada N, Sawada N, Taura D, Tsujimoto H, Chao TH, Tamura N, Mukoyama M, Nakao K.	The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential.	Endocrinology	147	1642-1653	2006
T. Ishii, H. Masuzaki, T. Tanaka, N. Arai, S. Yasue, N. Kobayashi, T. Tomita, M. Noguchi, J. Fujikura, K. Ebihara, K. Hosoda, and K. Nakao.	Augmentation of 11β -hydroxysteroid dehydrogenase type 1 in LPS-activated macrophages - Role of 11β -HSD1 in pro-inflammatory properties in macrophages.	FEBS Lett.	581	0349-354	2007
K. Ebihara, T. Kusakabe, M. Hirata, H. Masuzaki, F. Miyanaga, N. Kobayashi, T. Tanaka, H. Chusho, T. Miyazawa, T. Hayashi, K. Hosoda, Y. Ogawa, AM Depaoli, M. Fukushima, and K. Nakao.	Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.	J. Clin. Endocrinol. Metab.	92	532-541	2007

T. Tanaka, H. Masuzaki, S. Yasue, K. Ebihara, T. Shiuchi, T. Ishii, N. Arai, M. Hirata, H. Yamamoto, T. Hayashi, K. Hosoda, Y. Minokoshi, and K. Nakao.	Central Melanocortin Signaling Restores Skeletal Muscle AMP-Activated Protein Kinase Phosphorylation in Mice Fed a High-Fat Diet.	Cell Metab.	55	395-402	2007
M. Sone, H. Itoh, K. Yamahara, J. Yamashita, T. Yurugi-Kobayashi, A. Nonoguchi, Y. Suzuki, T-H. Chao, N. Sawada, Y. Fukunaga, K. Miyashita, K. Park, N. Oyamada, N. Sawada, D. Taura, N. Tamura, Y. Kondo, S. Nito, H. Suemori, N. Nakatsuji, S. Nishikawa, and K. Nakao.	Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration.	Arterioscler. Throm. Vasc. Biol.	27	2127-2134	2007
H. Iwakura, T. Akamizu, H. Ariyasu, T. Irako, K. Hosoda, K. Nakao, and K. Kangawa.	Effects of ghrelin administration on decreased growth hormone status in obese animals.	Am. J. Physiol. Endocrinol. Metab.	293	e819-e825	2007
K. Sawai, M. Mukoyama, K. Mori, M. Kasahara, M. Koshikawa, H. Yokoi, T. Yoshioka, Y. Ogawa, A. Sugawara, H. Nishiyama, S. Yamada, T. Kuwahara, M.A. Saleem, K. Shiota, O. Ogawa, M. Miyazato, K. Kangawa, and K. Nakao.	Expression of CCN1 (Cyr61) in developing, normal, and diseased human kidney.	Am. J. Physiol. Renal Physiol.	293	F1363-F1372	2007
K. Mori, and K. Nakao.	Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage.	Kidney Int.	71	967-970	2007
M. Noguchi, K. Hosoda, J. Fujikura, M. Fujimoto, H. Iwakura, T. Tomita, T. Ishii, N. Arai, M. Hirata, K. Ebihara, H. Masuzaki, H. Itoh, S. Narumiya, and K. Nakao.	Genetic and pharmacological inhibition of Rho-associated kinase II enhances adipogenesis.	J Biol Chem.	282	29574-29583	2007

N. Arai, H. Masuzaki, T. Tanaka, T. Ishii, S. Yasue, N. Kobayashi, T. Tomita, M. Noguchi, T. Kusakabe, J. Fujikura, K. Ebihara, M. Hirata, K. Hosoda, T. Hayashi, H. Sawai, Y. Minokoshi, and K. Nakao.	Ceramide and AMP-activated Protein Kinase are Two Novel Regulators of 11 β -Hydroxysteroid Dehydrogenase Type 1 Expression and Activity in Cultured Preadipocytes.	Endocrinology.	148	5268-77	2007
S. Nakano, Y. Inada, H. Masuzaki, T. Tanaka, S. Yasue, T. Ishii, N. Arai, K. Ebihara, K. Hosoda, K. Maruyama, Y. Yamazaki, N. Shibata, and K. Nakao.	Bezafibrate regulates the expression and enzyme activity of 11 β -hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.	Am J Physiol Endocrinol Metab	292	E1213-22	2007
L. Miyamoto, T. Toyoda, T. Hayashi, S. Yonemitsu, M. Nakano, S. Tanaka, K. Ebihara, H. Masuzaki, K. Hosoda, Y. Ogawa, G. Inoue, T. Fushiki, and K. Nakao.	Effect of acute activation of 5'-AMP-activated protein kinase on glycogen regulation in isolated rat skeletal muscle.	J Appl Physiol.	102	1007-13	2007
K. Park, H. Itoh, K. Yamahara, M. Sone, K. Miyashita, N. Oyamada, N. Sawada, D. Taura, M. Inuzuka, T. Sonoyama, H. Tsujimoto, Y. Fukunaga, N. Tamura, and K. Nakao.	Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases.	Endocrinology.	149	48-91	2007
T. Ogiwara, K. Nakao, T. Fukui, K. Fukiyama, K. Ueshima, K. Oba, T. Sato, T. Saruta, for the CASE-J Trial Group.	Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks	Hypertension	51	393-398	2008

雑誌 (寒川賢治)

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yoshihara F, Horio T, Nakamura S, Yoshii M, Ogata C, Nakahama H, Inenaga T, Kangawa K, Kawano Y.	Adrenomedullin reflects cardiac dysfunction, excessive blood volume, and inflammation in hemodialysis patients.	Kidney Int	68	1355-63	2005
Iwase T, Nagaya N, Fujii T, Itoh T, Ishibashi-Ueda H, Yamagishi M, Miyatake K, Matsumoto T, Kitamura S, Kangawa K.	Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia.	Circulation	111	356-62	2005

Obata H, Yanagawa B, Tanaka K, Ohnishi S, Kataoka M, Miyahara Y, Ishibashi-Ueda H, Kodama M, Aizawa Y, Kangawa K, Nagaya N.	CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis.	Biochem Biophys Res Commun.	356	Jun-60	2007
Nishida H, Horio T, Suzuki Y, Iwashima Y, Kamide K, Kangawa K, Kawano Y.	Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: Comparison with C-reactive protein and adiponectin.	Peptides.	29	599-605	2007
Yanagawa B, Kataoka M, Ohnishi S, Kodama M, Tanaka K, Miyahara Y, Ishibashi-Ueda H, Aizawa Y, Kangawa K, Nagaya N.	Infusion of adrenomedullin improves acute myocarditis via attenuation of myocardial inflammation and edema.	Cardiovasc Res.	76	110-8	2007
Itoh T, Obata H, Murakami S, Hamada K, Kangawa K, Kimura H, Nagaya N.	Adrenomedullin ameliorates lipopolysaccharide-induced acute lung injury in rats.	Am J Physiol Lung Cell Mol Physiol.	293	L446-52	2007
Yoshihara F, Ernst A, Morgenthaler NG, Horio T, Nakamura S, Nakahama H, Nakata H, Bergmann A, Kangawa K, Kawano Y.	Midregional proadrenomedullin reflects cardiac dysfunction in haemodialysis patients with cardiovascular disease.	Nephrol Dial Transplant.	22	Aug-63	2007
Watanabe K, Nishikimi T, Takamuro M, Yasuda K, Ishikawa Y, Tanabe S, Yamada O, Yagihara T, Suga S, Kangawa K, Matsuoka H, Echigo S.	Possible role of adrenomedullin in the regulation of Fontan circulation: mature form of plasma adrenomedullin is extracted in the lung in patients with Fontan procedure.	Regul Pept.	141	129-34	2007
Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, Yoshizawa T, Koyama T, Fukuchi J, Iimuro S, Moriyama N, Kawakami H, Murata T, Kangawa K, Nagai R, Shindo T.	The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity.	J Clin Invest.	118	29-39	2008

雑誌 (八十田明宏)

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ozasa A, Komatsu Y, Yasoda A, Miura M, Sakuma Y, Nakatsuru Y, Arai H, Itoh N, Nakao K.	Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells.	Bone	36	1056-64	2005
Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, Ozaki S, Nakao K.	High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass.	Osteoporos Int.	17	105-108	2005
K. Moriyama, T. Tagami, T. Usui, M. Naruse, T. Nambu, Y. Hataya, N. Kanamoto, Y. Li, A. Yasoda, H. Arai, and K. Nakao.	Antithyroid drugs inhibit thyroid hormone receptor-mediated transcription.	J. Clin. Endocrinol. Metab.	92	1066-1072	2007

Role of premature leptin surge in obesity resulting from intrauterine undernutrition

Shigeo Yura,^{1,6} Hiroaki Itoh,^{1,6} Norimasa Sagawa,^{1,*} Hiroshi Yamamoto,³ Hiroaki Masuzaki,² Kazuwa Nakao,² Makoto Kawamura,¹ Maki Takemura,¹ Kazuyo Kakui,¹ Yoshihiro Ogawa,^{4,5} and Shingo Fujii¹

¹Department of Gynecology and Obstetrics

²Department of Medicine and Clinical Science

Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho Sakyo-ku, Kyoto 606-8507, Japan

³Department of Surgery, Shiga University of Medical Science, Seta Otsu, Shiga 520-2192, Japan

⁴Department of Molecular Medicine and Metabolism, Medical Research Institute

⁵Center of Excellence Program for Frontier Research on Molecular Destruction and Reconstitution of Tooth and Bone

Tokyo Medical and Dental University, Tokyo 101-0062, Japan

⁶These authors contributed equally to this work.

*Correspondence: sagawa@clin.medic.mie-u.ac.jp

Summary

Intrauterine undernutrition is closely associated with obesity related to detrimental metabolic sequelae in adulthood. We report a mouse model in which offspring with fetal undernutrition (UN offspring), when fed a high-fat diet (HFD), develop pronounced weight gain and adiposity. In the neonatal period, UN offspring exhibited a premature onset of neonatal leptin surge compared to offspring with intrauterine normal nutrition (NN offspring). Unexpectedly, premature leptin surge generated in NN offspring by exogenous leptin administration led to accelerated weight gain with an HFD. Both UN offspring and neonatally leptin-treated NN offspring exhibited an impaired response to acute peripheral leptin administration on a regular chow diet (RCD) with impaired leptin transport to the brain as well as an increased density of hypothalamic nerve terminals. The present study suggests that the premature leptin surge alters energy regulation by the hypothalamus and contributes to “developmental origins of health and disease.”

Introduction

Obesity has increased at an alarming rate in Western countries and is now a world-wide public health problem (Flier, 2004). Obesity is often associated with insulin resistance, dyslipidemia, and hypertension, thus a concept of metabolic syndrome has been proposed (Masuzaki et al., 2001; Wajchenberg, 2000). Genetic factors and/or environmental factors, such as high-calorie diet in Western life style, have been considered to attribute to the prevalence of obesity (Flier, 2004). More recently, epidemiological and experimental evidence suggest that intrauterine undernutrition is closely associated with adulthood obesity related to detrimental metabolic sequelae (Breier et al., 2001; Godfrey and Barker, 2000; Ravelli et al., 1976), giving rise to the concept of “developmental origins of health and disease” (Breier et al., 2001; Gluckman and Hanson, 2004). Involvement of perinatal exposure to glucocorticoids or pancreatic maldifferentiation in the development of impaired glucose metabolism has been demonstrated (Breier et al., 2001; Gluckman and Hanson, 2004). However, the mechanism of developmental origins of obesity is yet to be clarified.

Leptin is an adipocyte-derived satiety factor that decreases food intake and increases energy expenditure, thereby stabilizing body adiposity in many species (Friedman and Halaas, 1998). Leptin deficient *ob/ob* mice show marked obesity that is restored by exogenous leptin treatment (Campfield et al., 1995; Halaas et al., 1995; Pelleymounter et al., 1995; Trayhurn et al., 1977). Leptin exerts its biological activities through long-form leptin receptors, expressed abundantly in the hypothalamus

(Flier, 2004). However, resistance to the satiety effect of leptin is a trait of obese subjects, as circulating leptin levels are well correlated with body fat mass (Ahren and Scheurink, 1998). It remains to be elucidated whether leptin resistance at the hypothalamus is associated with the onset of obesity or metabolic disorders in offspring with intrauterine growth restriction.

In mice, plasma leptin levels rise transiently during neonatal period, termed as “neonatal leptin surge” (Ahima et al., 1998). In neonatal period, leptin alters hypothalamic neuropeptide expression and metabolic rate before exerting its anorectic effect (Ahima and Hileman, 2000; Mistry et al., 1999; Proulx et al., 2002). Moreover, neurotrophic action of leptin was recently demonstrated, which is operative only in early developmental stage, but not in adult individuals (Bouret et al., 2004a; Bouret et al., 2004b). Therefore, it is suggested that leptin surge is involved in the formation of energy-regulation circuits in the hypothalamus. However, long-term effects of physiological or pathophysiological leptin surge on hypothalamic neuronal circuits are yet to be fully clarified. Here, we demonstrate a mouse model of intrauterine undernutrition in which premature leptin surge contributes to developmental origins of obesity.

Results and discussion

Development of obesity and related metabolic disorders in offspring with intrauterine undernutrition

Maternal body weight gain during pregnancy was significantly suppressed by 30% restriction of maternal food supply (Figure




Figure 1. Exaggerated diet-induced weight gain in offspring with fetal undernutrition (UN) compared to offspring with normal fetal nutrition (NN)

A) Maternal body weight change during pregnancy. Food restriction started on day 10.5 postcoitum as described in the Experimental Procedures. Number of dams in each group is seven to eight.

B) Fetal weights at 18.5 d.p.c. in three litters in both groups. Weights of both male and female fetuses were plotted without discrimination. Litter sizes of demonstrated litters are nine to ten in both NN group and UN group.

C) Neonatal catch-up growth in UN offspring. $n = 96$ from 12 litters for each group. Average body weights of 96 pups including both male and female pups in each group are shown.

D) Exaggerated weight gain in UN offspring on an HFD but not on an RCD. HFD was started at 9 weeks of age.

E) Plasma leptin concentrations at 17 weeks of age. Dark and light purple lines (A, C, and D), dots (B) and columns (E) indicate dams or offspring with undernutrition. * $p < 0.05$ versus NN offspring; n.s.: not significant. In the experiment for (D) and (E), all pups were nursed at a rate of 8 pups per dam until weaning. Only male animals were used for further experiments. $n = 7-15$ for each group in (D) and (E). Error bars represent SEM.

1A). The UN offspring were born small (Figure 1B) with reduced lipid accumulation in the subcutaneous adipose tissue (data not shown) but caught up in body weight to NN offspring within 10 days after birth (Figure 1C). They showed no apparent difference in body weight and fat mass on an RCD thereafter (Figure 1D; Table 1). However, UN offspring developed pronounced weight gain and adiposity (40% and 30% larger in subcutaneous and epididymal fat depots, respectively) compared to NN offspring, when fed a HFD commencing at 9 weeks of age (Fig-

ure 1D; Table 1). An obesity-prone phenotype of UN offspring was confirmed in an additional three independent experiments. Serum leptin levels in UN offspring were significantly higher than those in NN offspring on an HFD ($p < 0.05$), in parallel with their adiposity (Figure 1E; Table 1). These observations are in agreement with previous reports on rodent models of fetal undernutrition and catch-up growth (Ozanne and Hales, 2004)

The UN offspring did not differ significantly from NN offspring with regard to calorie intake during the development of

Table 1. Adiposity and lipid profiles of NN and UN offspring

	NN Offspring		UN Offspring	
	RCD ($n = 15$)	HFD ($n = 13$)	RCD ($n = 7$)	HFD ($n = 11$)
Body mass index (g/cm^2)	0.33 ± 0.01	0.37 ± 0.01	0.31 ± 0.01	0.42 ± 0.01^a
Subcutaneous adipose tissue (g)	0.52 ± 0.05	1.12 ± 0.10	0.42 ± 0.04	1.67 ± 0.14^a
Epididymal adipose tissue (g)	0.58 ± 0.06	1.50 ± 0.15	0.48 ± 0.05	1.98 ± 0.09^b
Leptin mRNA expression in subcutaneous adipose tissue (AU)	2.84 ± 0.69	26.26 ± 5.28	2.99 ± 0.46	21.39 ± 4.54
Serum triglyceride (mg/dl)	192.1 ± 18.2	199.6 ± 20.2	134.8 ± 9.2^a	125.0 ± 10.9^a
Serum total cholesterol (mg/dl)	101.3 ± 4.0	166.3 ± 16.9	92.6 ± 5.2	222.0 ± 5.8^a
Serum HDL cholesterol (mg/dl)	47.6 ± 7.0	97.7 ± 12.7	54.0 ± 5.9	132.7 ± 6.5^b
Serum free fatty acids (mg/dl)	0.61 ± 0.04	0.75 ± 0.06	0.69 ± 0.06	0.50 ± 0.00^b

Samples are collected from offspring with normal intrauterine nutrition (NN) and from offspring with intrauterine undernutrition (UN) on an RCD or on an HFD at 17 weeks of age.

Differences between RCD group and HFD group were not demonstrated in both groups.

^a $p < 0.01$ versus NN offspring.

^b $p < 0.05$ versus NN offspring.




Figure 2. Blunted diet-induced thermogenesis and impaired glucose metabolism in UN offspring compared to NN offspring

A) Average daily calorie intake from 9 to 17 weeks of age on an RCD or on an HFD in NN and UN offspring, $n = 7-15$. **B)** Resting rectal body temperature, **C)** O₂ consumption, and **D)** CO₂ production were measured in NN and UN offspring on an RCD or on an HFD at 13 weeks of age. n.s.: not significant, $n = 7-15$. **E)** Glucose tolerance test was performed at 17 weeks of age on an RCD. **F and G)** Insulin sensitivity was examined at 19 weeks of age on an RCD (**F**) and on an HFD (**G**). Initial glucose levels of UN and NN offspring were 100.5 ± 3.3 and 109.3 ± 5.8 mg/dl in (**E**), 95.5 ± 3.3 and 113.0 ± 4.9 mg/dl in (**F**), and 186 ± 14.8 and 157.1 ± 8.3 mg/dl in (**G**), respectively. # $p < 0.05$ versus NN offspring, $n = 6-11$ in another series of experiments from that in (**A-D**). Dark and light purple columns (**A, B, C, and D**) and lines (**E, F, and G**) indicate UN offspring. Error bars represent SEM.

diet-induced weight gain (Figure 2A). On an HFD, NN offspring showed elevated rectal temperature and increased O₂ consumption and CO₂ production (Figures 2B-2D). On the other hand, UN offspring did not show such changes in energy metabolism, suggesting impaired diet-induced thermogenesis (DIT; Lowell and Spiegelman, 2000). These characteristics of energy metabolism in UN offspring are consistent with the "thrifty phenotype hypothesis" according to which undernutri-

tion in utero programs offspring to conserve energy for survival under conditions of scarce food supply after birth (Hales and Barker, 2001). A significant elevation of uncoupling proteins' (UCP-1 and -2) mRNA expression in the brown adipose tissue (BAT) of both UN and NN offspring on an HFD (data not shown) could not explain clearly the mechanisms of blunted diet-induced thermogenesis in UN offspring. Nonetheless, an HFD significantly augmented free fatty acid (FFA) concentrations in NN offspring, but not in UN offspring (Table 1). Since the release of FFA from WAT stimulates mitochondrial thermogenesis in BAT (Ricquier and Bouillaud, 2000), altered lipid metabolism, such as low FFA levels in UN offspring, may partly contribute to the blunted diet-induced thermogenesis in these animals. The UN offspring also showed impaired glucose metabolism and lipid profiles compared to NN offspring (Figures 2E and 2F; Table 1). HFD deteriorated an impairment of both glucose (Figure 2G) and lipid metabolism (Table 1). These findings indicate that intrauterine undernutrition in the present study is an appropriate model for the elucidation of fetal origins of metabolic syndrome.

Neonatal premature leptin surge is associated with obesity

During the catch-up growth, the peak of leptin surge, a transient rise of serum leptin levels in mice neonates (Ahima et al., 1998) was advanced (8-10 days after birth) in UN offspring compared to that in NN offspring (16 days after birth; Figure 3A). Profiles of neonatal leptin concentrations in UN and NN offspring were fundamentally parallel with leptin mRNA expression in subcutaneous adipose tissue (Figure 3B), suggesting that altered leptin production is responsible for premature onset of leptin surge. UN offspring showed hyperglycemia and hyperinsulinemia at 8 days of age (data not shown). Increase in insulin signal augments leptin production from adipose tissue (Considine, 2001). It is likely that intrauterine undernutrition induced, at least partly through altered glucose metabolism, premature leptin surge in these offspring. According to Ahima et al. (1998), the timing for the leptin surge in mice not subjected to intrauterine undernutrition is day 10, while we observed a peak leptin surge occurring at day 16. The discrepancy might be due to differences in number of pups in each litter, i.e., only five pups per litter in the report by Ahima et al. and eight to nine pups per litter in the present study.

To examine whether premature leptin surge is associated with pronounced weight gain in UN offspring on an HFD, we induced premature leptin surge in NN offspring by exogenous administration of leptin from day 5.5 to day 10.5 of life. In addition to the significant elevation of endogenous leptin surge observed in UN offspring compared to NN offspring demonstrated in Figure 3A, serum leptin concentrations at 5.5 days of age in UN offspring were also higher than those in NN offspring in another series of experiments (data not shown). Therefore, we determined the period of exogenous leptin administration as above. Serum leptin concentration after subcutaneous leptin treatment in pups at 5.5 days of age reached its peak (3955 ± 445 ng/ml) at 2 hr after injection and returned to levels similar to vehicle-treated pups by 8 hr after injection. During the 6 days of daily leptin treatment, NN offspring treated with leptin tended to gain less weight compared to vehicle-treated groups, but the difference was not significant. This is consistent with previous findings that leptin does not exert its




Figure 3. Premature onset of leptin surge in UN offspring as a trigger of exaggerated weight gain on an HFD

A) Serum leptin concentrations and **(B)** leptin mRNA expression in subcutaneous adipose tissue during neonatal development. Both male and female pups were assayed without discrimination. Note the earlier occurrence of leptin surge in UN offspring.

C) Body weight changes of NN offspring during neonatal leptin or vehicle treatment. Average body weights of both male and female pups are shown. $n = 20-22$.

D) Exaggerated weight gain on an HFD in NN offspring with early neonatal leptin treatment. HFD was started at 9 weeks of age.

E) Plasma leptin concentrations at 17 weeks of age in NN offspring with or without early neonatal leptin treatment.

F) Average daily calorie intake from 9 to 17 weeks of age on an RCD or HFD. Dark and light orange lines (**C** and **D**) and columns (**E** and **F**) indicate offspring with neonatal leptin treatment. Neo-Lep: offspring with neonatal leptin treatment; Neo-Veh: offspring with neonatal vehicle treatment. * $p < 0.05$ versus control; A.U.: arbitrary units. $n = 8-10$ for each column or line except for (**C**). Error bars represent SEM.

anorectic effect until the third week of life (Mistry et al., 1999; Proulx et al., 2002). They caught up in growth by the time of weaning (Figure 3C). Body weight and fat mass of leptin-treated NN offspring on an RCD thereafter (Figure 3D for body weight and 0.36 ± 0.05 versus 0.31 ± 0.04 g for subcutaneous adipose mass). On an HFD, however, leptin-treated NN offspring developed accelerated weight gain and adiposity compared to vehicle-treated groups (Figure 3D for body weight and 2.02 ± 0.11

versus 1.63 ± 0.17 g for subcutaneous adipose mass). An obesity-prone phenotype of offspring with neonatal leptin treatment was confirmed in an additional two independent experiments. The serum leptin levels in NN offspring with neonatal leptin treatment were significantly increased compared to vehicle-treated groups during the development of diet-induced obesity (Figure 3E). Calorie intake of leptin-treated NN offspring was similar to that of vehicle-treated groups on an HFD (Figure 3F), implying an involvement of decreased energy expenditure in the aggravation of HFD-induced obesity. Thus, as NN offspring with neonatal leptin treatment were phenotypically indistinguishable from UN offspring, premature onset of leptin surge is causally related to pronounced obesity in UN offspring on an HFD.

Leptin resistance in offspring with exposure to premature leptin surge

Resistance to the weight-reducing effect of leptin is a feature of obesity with hyperleptinemia (Flier, 2004; Friedman, 2000). It has been described that high-calorie diet induces obesity with leptin resistance by at least two different mechanisms (El-Haschimi et al., 2000), an impairment of leptin transfer through the blood-brain barrier (BBB) and/or a disturbed signal transfer in the hypothalamus. To examine the response to exogenous leptin administration in UN and NN offspring, we performed an acute intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) injection of leptin in UN and NN offspring on an RCD at 8 to 10 weeks of age when they were of similar weight. Animals used in this section are a new set of mice not used in other studies. No significant difference was observed in serum leptin levels between UN and NN offspring 2 hr after i.p. injection of leptin (74.0 ± 13.9 versus 72.2 ± 6.1 ng/ml; $n = 8$) in a preliminary experiment. In NN offspring, body-weight increase was significantly suppressed 12 hr after i.p. leptin treatment (Figure 4A; $p < 0.05$), whereas no such effects were observed in UN offspring. In this study, i.p. injection of leptin stimulated phosphorylation of signal transducer and activator of transcription 3 (STAT3), an intracellular signaling mediator of leptin action (El-Haschimi et al., 2000), in the hypothalamus of NN offspring, but not of UN offspring (Figure 4B). Then we detected c-Fos positive cells, i.e., activated neurons (Elmqvist, 2001), after i.p. injection of leptin. The number of c-Fos-positive cells was smaller in UN offspring than in NN offspring in the hypothalamic arcuate nucleus (ARH; Figure 4C) and paraventricular hypothalamus (PVH) nuclei mediating hypothalamic leptin signaling (Schwartz et al., 2000; Wilding, 2002; Figure 4D). By contrast, the response to i.c.v. injection of leptin in UN offspring was not blunted with regard to body weight (Figure 4E) and STAT3 phosphorylation in the hypothalamus (Figure 4F) compared to NN offspring. We also obtained essentially the same data in NN offspring treated neonatally with leptin (Figures 4G and 4H). These observations suggest impaired brain leptin transport (Caro et al., 1996) in UN offspring as well as in NN offspring treated neonatally with leptin. This is supported by a significant reduction in mRNA expression of the short-form leptin receptor, Ob-Ra, which is suggested to play a role in the transport of leptin across the BBB (Hileman et al., 2002) in the hypothalamus of UN offspring (1.23 ± 0.16 arbitrary units [AU]; $n = 7$) compared to that of NN offspring (2.09 ± 0.15 AU; $n = 10$; $p < 0.01$). It is likely that a premature leptin surge in UN offspring leads to resistance to peripherally administered lep-




Figure 4. Resistance to peripheral leptin in adult UN and NN offspring with neonatal leptin treatment

A) Body weight changes following intraperitoneal (i.p.) leptin administration in UN and NN offspring.

B) Phosphorylated STAT3 in the entire hypothalamus after i.p. leptin administration.

C) The number of c-Fos-positive cells in arcuate nucleus of the hypothalamus after acute leptin administration at 10 weeks of age. Mean number of cells with c-Fos-like immunoreactivity after saline vehicle treatment was 9.5 ± 0.7 ($n = 4$) with no remarkable difference between UN and NN offspring.

D) The number of c-Fos-positive cells in paraventricular hypothalamus in the same brain tissues as in (C). Mean number of cells with c-Fos-like immunoreactivity after saline vehicle treatment was 8.5 ± 0.7 ($n = 4$) with no remarkable difference between UN and NN offspring

E) Body-weight changes following intracerebroventricular (i.c.v.) leptin administration.

F) Phosphorylated STAT3 in the entire hypothalamus after i.c.v. leptin administration.

G) Body-weight changes following i.p. leptin administration in NN offspring with neonatal leptin or vehicle treatment.

H) Body-weight changes following i.c.v. leptin administration in NN offspring with neonatal leptin or vehicle treatment.

All procedures were performed at 8–10 weeks of age. Lep: acute leptin administration; Veh: acute vehicle administration; Neo-Lep: neonatal leptin treatment; Neo-Veh: neonatal vehicle treatment; n.s.: not significant; $n = 8-12$; A.U.: arbitrary unit. Error bars represent SEM.

tin, accompanied by impaired leptin transport to the brain. However, neither UN offspring nor NN offspring with neonatal leptin treatment developed obesity on an RCD, suggesting that as-yet-unidentified compensatory mechanisms are operative.

On an HFD, both UN offspring and NN offspring with neonatal leptin treatment showed hyperleptinemia concomitant with pronounced obesity, indicating that they are less sensitive to circulating leptin than NN offspring without neonatal leptin treatment. It remains to be elucidated how resistance to circulating leptin might be involved in the pronounced weight gain on a high fat diet in the present study.

The hypothalamus is responsible for the development of obesity

Since the ARH plays a critical role in the central regulation of thermogenesis, we chemically injured the ARH of UN and NN offspring by neonatal administration of monosodium glutamate (MSG; Olney, 1969), which is known to induce obesity through reduced thermogenesis (Tokuyama and Himms-Hagen, 1986). No significant difference in body weight was observed between MSG-treated UN offspring and MSG-treated NN offspring on a HFD (Figure 5A), implying that the hypothalamic area damaged by MSG (i.e., ARH) is responsible for pronounced weight gain in UN offspring on a HFD. Nevertheless, the possibility cannot be fully neglected that rapid body-weight gain induced by hypothalamic ablation with MSG obscures the augmentation of diet-induced obesity after neonatal exposure to premature leptin surge. In this study, we found that in both wild-type UN offspring with endogenous premature leptin surge and NN offspring treated neonatally with exogenous leptin, the density of nerve terminals containing neuropeptide Y (NPY) or cocaine and amphetamine-regulated transcript (CART) was increased, in PVH that receives the downstream leptin signaling from ARH (Schwartz et al., 2000; Wilding, 2002; Figures 5B and 5C). These alterations were preserved even after pronounced weight gain on an HFD (data not shown). Although many animal and human studies implicate that CART is involved in thermogenesis and has an inhibitory effect against development of obesity (Hunter et al., 2004), there is some controversy about anorexigenic effect of CART neuropeptide (Kong et al., 2003). It will be interesting to elucidate the possible relationship between such hypothalamic structural changes and the development of pronounced HFD-induced obesity.

Proulx et al. (2002) revealed that leptin increased proopiomelanocortin (POMC) expression and decreased NPY and leptin-receptor expression in the hypothalamus in the developing rat. Moreover, Bouret et al. (2004a) demonstrated that leptin promotes neural projections from ARH to other hypothalamic nuclei including PVH. These findings suggest that premature onset or augmentation of neonatal leptin surge might induce organic and/or functional alterations in the developing hypothalamus.

Catch-up growth is associated with adulthood obesity in mice (Ozanne and Hales, 2004) as well as in humans (Stettler et al., 2002). The present study demonstrated that onset of leptin surge is advanced in UN offspring during the catch-up period and that this premature leptin surge contributes to a conversion to an obesity-prone phenotype in UN offspring. Impairment of leptin transfer through the BBB in the hypothalamus may be linked with this phenotypic conversion in wild-type offspring. In addition, the hypothalamic nuclei are responsible for




Figure 5. Involvement of the hypothalamic regulation in the exaggeration of diet-induced obesity in offspring with intrauterine undernutrition

A) Body-weight changes of UN and NN offspring with neonatal monosodium glutamate (MSG) treatment. Mice were fed an RCD or an HFD from 9 weeks of age. $n = 10$ – 12 .

B) Increased nerve terminal densities of NPY in PVH of UN offspring as well as NN offspring with neonatal leptin treatment.

C) Increased nerve terminal densities of CART in PVH of UN offspring as well as NN offspring with neonatal leptin treatment.

Figures in (B) and (C) are representative of at least four mice in each study group. Neo-Lep: neonatal leptin treatment; Neo-Veh: neonatal vehicle treatment. Scale bar, 20 μ m. Error bars represent SEM.

the onset of pronounced adiposity on an HFD, as demonstrated in MSG-treated UN offspring. Altered hypothalamic neural structure, including adipostatic and counter-regulatory signals, may be involved in the programming of increased adiposity by premature leptin surge. We also observed that increased adiposity on an HFD was programmed by exogenously treated premature leptin surge even in the absence of leptin signal in *ob/ob* background (S.Y., H.I., and N.S., unpublished data). This implies that altered hypothalamic neural structure in offspring with exposure to premature leptin surge might be involved in the programming of increased adiposity in addition to a decrease in sensitivity to circulating leptin.

Epidemiological evidence suggests that intrauterine undernutrition predisposes humans to obesity and metabolic syndrome later in life (Godfrey and Barker, 2000; Ravelli et al., 1976; Wajchenberg, 2000). The “fetal programming” hypothesis postulates that undernutrition in utero causes permanent

changes in structure, physiology, and metabolism to adapt to restricted nutritional supply (thrifty phenotype; Godfrey and Barker, 2000). When the nutritional supply is excessive (e.g., exposure to a high-calorie diet in Western life style), such thrifty traits by fetal programming become maladaptive, that is, contribute to the development of obesity and metabolic syndrome (Wells, 2003). Currently, neonates born small for gestational age are increasing in number (Ananth et al., 2004). They show a transient overshoot in plasma leptin levels during the catch-up period (Jaquet et al., 1999). The present findings suggest the possibility that premature rise in plasma leptin levels is involved in fetal programming in these neonates and contributes to obesity and subsequent metabolic disorders after exposure to a high-calorie diet.

In conclusion, this study demonstrates that the timing of neonatal leptin surge determined by fetal nutrition contributes to the development of accelerated obesity in later life. This study also highlights the leptin surge as a target for therapeutic intervention in the developmental origins of health and disease.

Experimental procedures

Development of a mouse model of undernutrition in utero

Pregnant C57Bl/6 mice were purchased 6.5 days postcoitum (d.p.c.) from Japan Central Laboratories for Experimental Animals (Tokyo, Japan) and were divided into two groups 10.5 d.p.c. Dams were individually housed with free access to water during 14 hr/10 hr light/dark cycles (0700 hr, 2100 hr) in a specific-pathogen-free facility. The daily food supply of one group was restricted to 70% of the food consumed by the other group, fed ad libitum, based on the data of the previous day, from 10.5 d.p.c. to the day of delivery of the pups. Dams in the food-restriction group were given 2.5 g of extra food supply in the evening of 18.5 d.p.c., just before the initiation of parturition, to prevent them from eating their own pups. Litter size was examined on 1.5 days after delivery. Offspring from dam with less than 8 pups or larger than 10 pups were excluded from the study. To control litter size to 8 or 9 per dam, pups were culled or moved to other dams and were fostered until weaning, depending on the total pup numbers in every experimental course. Pups were weaned on to RCD at 21.5 days of age. Only male offspring were used in any experiments after weaning from dams. Each experimental group in all experiments consists of offspring from at least three litters. Caloric intakes by offspring after weaning were measured in groups (three to four per cage) twice a week. All experimental procedures were approved by the Animal Research Committee, Graduate School of Medicine, Kyoto University.

High fat diet (HFD)

At 9 weeks of age, HFD (containing 60% lipid by calorie mainly by lard, formula D12492, Research Diets Inc., New Brunswick, NJ, <http://www.researchdiets.com/formulas/item/dio.htm>) or RCD (containing 12% lipid and 20.0% protein by calorie, 3.44 kcal/g, CLEA Japan Inc., Tokyo, Japan) was supplied to NN and UN offspring.

Energy metabolism analysis

Body temperature was determined by measuring rectal core temperature 25 times with a digital thermometer (TD-320, Shibaura Electronics Co. Ltd., Tokyo, Japan). Oxygen (O_2) consumption and CO_2 production in the resting state were measured with an O_2/CO_2 metabolism measuring system (Model MK-5000, Muromachikikai, Tokyo, Japan; Nakagawa et al., 2000).

Glucose metabolism

Glucose tolerance test was performed by i.p. administration of glucose (1.5 mg/g body weight) after overnight fasting. Insulin sensitivity was examined by i.p. administration of insulin (0.75 mU/g body weight) after overnight fasting. Blood glucose concentrations were determined by Glutest Ace R (Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya, Japan).

Blood sample assays

Serum concentrations of triglyceride, total cholesterol, and HDL cholesterol were determined using the Fuji DRI-CHEM system (Fuji Photo Film Co. Ltd., Tokyo, Japan). Serum leptin concentrations were determined by Mouse Leptin ELISA (R&D Systems, Inc., Minneapolis, Minnesota).

Quantitative RT-PCR analysis

Total RNA from subcutaneous adipose tissue was extracted as previously described (Masuzaki et al., 1997). Gene expression of leptin was determined by quantitative RT-PCR using TaqMan Probes (Applied Biosystems, Foster City, California), according to the manufacturer's recommendation. Primers and fluorescent probe for leptin are as follows: forward, ttcacacacg cagtcggtatc; reverse, tggctcatctggacaactca; TaqMan Probe, tgaagtccaag ccagtgaccctctgc. Those for short-form leptin receptor (Ob-Ra) are as follows: forward, ctgaattccaaaagagaacgga, reverse, ggaagtggtgagattgggtg atct, TaqMan Probe, tgaagtctctcatgaccact. Ribosomal RNA contents or GAPDH mRNA expression was used as an internal control.

Neonatal leptin or MSG treatment

Leptin (2.5 µg/g body weight/day) (kind donation from Amgen Inc., Thousand Oaks, California) or vehicle saline was subcutaneously administered to NN offspring daily from 5.5 to 10.5 days of age. Monosodium glutamate (MSG; 2 mg/g body weight/day) was subcutaneously administered to NN and UN offspring from 1.5 to 5.5 days of age (Olney, 1969).

Acute leptin administration to adult offspring

Leptin was administered i.p. (2.5 µg/g body weight) or i.c.v. (0.5 µg/mouse; Aizawa et al., 2000) to NN and UN offspring at 1900 hr at 8 weeks of age, and body-weight changes and food consumption were measured for the next 12 hr. The i.c.v. placement technique was confirmed by dye injection in preliminary experiment. Additionally, scanty backflow was observed after each injection.

Mice with confirmed leptin resistance or leptin sensitivity in UN offspring and NN offspring, respectively, by a single dose of i.p. leptin treatment were used for the following phosphorylated STAT3 and c-Fos immunoreactivity experiment.

Detection of phosphorylated STAT3 in the hypothalamus

Phosphorylated STAT3 protein in the entire hypothalamus of UN offspring was measured 30 min after acute i.p. (1.5 µg/g body weight) or i.c.v. (0.2 µg/mouse) administration of leptin at 10 weeks of age. Protein extraction was performed as previously described (Itoh et al., 1998). An ECL Advance kit (Amersham Bioscience Corp., Piscataway, New Jersey) was used with anti-mouse pSTAT3 antibody (1:1,000, overnight; Cell Signaling Technology, Beverly, Massachusetts) and anti-rabbit IgG antibody with HRP (1:20,000, 1 hr; Cell Signaling Technology, Beverly, Massachusetts).

Detection of activated neurons by c-Fos immunoreactivity

To prevent stress-induced c-Fos expression, intraperitoneal cannulas were placed 7 days before treatment. Leptin (0.5 µg/g body weight) or vehicle saline was gently administered through the i.p. cannulas after 2 hr of fasting at 10 weeks of age. Peak serum leptin levels were observed at 15 min after the i.p. leptin injection on preliminary examination (data not shown). The entire hypothalamus was sampled 135 min after the treatment and processed for immunohistochemistry as described previously (Yamamoto et al., 2002), using rabbit polyclonal antibody against c-Fos (1:50,000, 6 days at 4°C; Oncogen Research Products, San Diego, California). The number of c-Fos-positive cells in ARH (at -1.46 mm behind the bregma) and PVH (at -1.06 mm behind the bregma) were counted in approximately the same plane by a researcher who was blind with respect to the treatment. The distance of sections behind bregma was determined according to the atlas of mouse brain (Paxinos and Franklin, 2001).

Neuroanatomical analysis

Immunohistochemical analysis of the hypothalamus was performed as above. The antibodies used were anti-NPY antibody (1:5,000, 6 days at 4°C; Chemicon International, Temecula, California) or anti-CART antibody (1:10,000, 6 days at 4°C; Phoenix Pharmaceuticals Inc., Belmont, California). Mice were sacrificed at 12 weeks of age. The NPY and CART immunostaining was examined on the sections at -1.06 mm behind the

bregma. But we compared CART immunostaining on the sections at -0.82 mm behind the bregma in NN offspring with neonatal vehicle or leptin treatment because we did not obtain exact matches at -1.06 mm behind the bregma.

Statistics

Data are expressed as mean ± SEM and the statistical significance of differences in mean values was assessed using Student's t test or analysis of variance (ANOVA) with Fisher's protected least-significant-difference test, as appropriate. Differences among means were considered significant at values of $p < 0.05$.

Acknowledgments

The authors acknowledge Mrs. Akiko Kishimoto Kuzuoka, Mrs. Akiko Abe, and Ms. Aoi Komatsu for secretarial and technical assistance. The authors also acknowledge Dr. Tsuyoshi Mori for helping with the immunohistochemical staining and Dr. Mutsuo Taiji, Sumitomo Pharmaceuticals Co. Ltd, for helping in the analysis of energy metabolism. This work was supported in part by Grants-In-Aid for the Scientific Research from the Ministry of Education, Science, and Culture, Japan (Nos. 14704042, 15390504, 15659393, 16390475) and by grants from the Ministry of Health and Welfare, the Smoking Research Foundation, the Mitsui Sumitomo Insurance Welfare Foundation, Astellas Foundation for Research on Metabolic Disorders, Ono Medical Research Foundation, and Daiwa Securities Health Foundation. We also thank Amgen Inc. (Thousand Oaks, California) for kind donation of leptin.

Received: December 16, 2004

Revised: April 7, 2005

Accepted: May 17, 2005

Published: June 7, 2005

References

- Ahima, R.S., and Hileman, S.M. (2000). Postnatal regulation of hypothalamic neuropeptide expression by leptin: implications for energy balance and body weight regulation. *Regul. Pept.* 92, 1-7.
- Ahima, R.S., Prabakaran, D., and Flier, J.S. (1998). Postnatal leptin surge and regulation of circadian rhythm of leptin by feeding. Implications for energy homeostasis and neuroendocrine function. *J. Clin. Invest.* 101, 1020-1027.
- Ahren, B., and Scheurink, A.J. (1998). Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. *Eur. J. Endocrinol.* 139, 461-467.
- Aizawa, A.M., Ogawa, Y., Masuzaki, H., Ebihara, K., Satoh, N., Iwai, H., Matsuoka, N., Hayashi, T., Hosoda, K., Inoue, G., et al. (2000). Pathophysiological role of leptin in obesity-related hypertension. *J. Clin. Invest.* 105, 1243-1252.
- Ananth, C.V., Balasubramanian, B., Demissie, K., and Kinzler, W.L. (2004). Small-for-gestational-age births in the United States: an age-period-cohort analysis. *Epidemiology* 15, 28-35.
- Bouret, S.G., Draper, S.J., and Simerly, R.B. (2004a). Formation of projection pathways from the arcuate nucleus of the hypothalamus to hypothalamic regions implicated in the neural control of feeding behavior in mice. *J. Neurosci.* 24, 2797-2805.
- Bouret, S.G., Draper, S.J., and Simerly, R.B. (2004b). Trophic action of leptin on hypothalamic neurons that regulate feeding. *Science* 304, 108-110.
- Breier, B.H., Vickers, M.H., Ikenasio, B.A., Chan, K.Y., and Wong, W.P. (2001). Fetal programming of appetite and obesity. *Mol. Cell. Endocrinol.* 185, 73-79.
- Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., and Burn, P. (1995). Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. *Science* 269, 546-549.
- Caro, J.F., Kolaczynski, J.W., Nyce, M.R., Ohannesian, J.P., Opentanova, I., Goldman, W.H., Lynn, R.B., Zhang, P.L., Sinha, M.K., and Considine, R.V.

- (1996). Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. *Lancet* 348, 159–161.
- Considine, R.V. (2001). Regulation of leptin production. *Rev. Endocr. Metab. Disord.* 2, 357–363.
- El-Haschimi, K., Pierroz, D.D., Hileman, S.M., Bjorbaek, C., and Flier, J.S. (2000). Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. *J. Clin. Invest.* 105, 1827–1832.
- Elmqvist, J.K. *Suppl.* 5(2001). Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. *Int. J. Obes. Relat. Metab. Disord.* 25, S78–S82.
- Flier, J.S. (2004). Obesity wars: molecular progress confronts an expanding epidemic. *Cell* 116, 337–350.
- Friedman, J.M. (2000). Obesity in the new millennium. *Nature* 404, 632–634.
- Friedman, J.M., and Halaas, J.L. (1998). Leptin and the regulation of body weight in mammals. *Nature* 395, 763–770.
- Gluckman, P.D., and Hanson, M.A. (2004). Living with the past: evolution, development, and patterns of disease. *Science* 305, 1733–1736.
- Godfrey, K.M., and Barker, D.J. (2000). Fetal nutrition and adult disease. *Am. J. Clin. Nutr.* 71, 1344S–1352S.
- Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz, D., Lallone, R.L., Burley, S.K., and Friedman, J.M. (1995). Weight-reducing effects of the plasma protein encoded by the obese gene. *Science* 269, 543–546.
- Hales, C.N., and Barker, D.J. (2001). The thrifty phenotype hypothesis. *Br. Med. Bull.* 60, 5–20.
- Hileman, S.M., Pierroz, D.D., Masuzaki, H., Bjorbaek, C., El-Haschimi, K., Banks, W.A., and Flier, J.S. (2002). Characterization of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. *Endocrinology* 143, 775–783.
- Hunter, R.G., Philpot, K., Vicentic, A., Dominguez, G., Hubert, G.W., and Kuhar, M.J. (2004). CART in feeding and obesity. *Trends Endocrinol. Metab.* 15, 454–459.
- Itoh, H., Bird, I.M., Nakao, K., and Magness, R.R. (1998). Pregnancy increases soluble and particulate guanylate cyclases and decreases the clearance receptor of natriuretic peptides in ovine uterine, but not systemic, arteries. *Endocrinology* 139, 3329–3341.
- Jaquet, D., Leger, J., Tabone, M.D., Czernichow, P., and Levy-Marchal, C. (1999). High serum leptin concentrations during catch-up growth of children born with intrauterine growth retardation. *J. Clin. Endocrinol. Metab.* 84, 1949–1953.
- Kong, W.M., Stanley, S., Gardiner, J., Abbott, C., Murphy, K., Seth, A., Connolly, I., Ghatei, M., Stephens, D., and Bloom, S. (2003). A role for arcuate cocaine and amphetamine-regulated transcript in hyperphagia, thermogenesis, and cold adaptation. *FASEB J.* 17, 1688–1690.
- Lowell, B.B., and Spiegelman, B.M. (2000). Towards a molecular understanding of adaptive thermogenesis. *Nature* 404, 652–660.
- Masuzaki, H., Ogawa, Y., Sagawa, N., Hosoda, K., Matsumoto, T., Mise, H., Nishimura, H., Yoshimasa, Y., Tanaka, I., Mori, T., and Nakao, K. (1997). Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. *Nat. Med.* 3, 1029–1033.
- Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl, J.R., and Flier, J.S. (2001). A transgenic model of visceral obesity and the metabolic syndrome. *Science* 294, 2166–2170.
- Mistry, A.M., Swick, A., and Romsos, D.R. (1999). Leptin alters metabolic rates before acquisition of its anorectic effect in developing neonatal mice. *Am. J. Physiol.* 277, R742–R747.
- Nakagawa, T., Tsuchida, A., Itakura, Y., Nonomura, T., Ono, M., Hirota, F., Inoue, T., Nakayama, C., Taiji, M., and Noguchi, H. (2000). Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. *Diabetes* 49, 436–444.
- Olney, J.W. (1969). Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. *Science* 164, 719–721.
- Ozanne, S.E., and Hales, C.N. (2004). Lifespan: catch-up growth and obesity in male mice. *Nature* 427, 411–412.
- Paxinos, G., and Franklin, K.B.J. (2001). *The Mouse Brain in Stereotaxic Coordinates* (San Diego, CA: Academic Press).
- Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Hecht, R., Winters, D., Boone, T., and Collins, F. (1995). Effects of the obese gene product on body weight regulation in *ob/ob* mice. *Science* 269, 540–543.
- Proulx, K., Richard, D., and Walker, C.D. (2002). Leptin regulates appetite-related neuropeptides in the hypothalamus of developing rats without affecting food intake. *Endocrinology* 143, 4683–4692.
- Ravelli, G.P., Stein, Z.A., and Susser, M.W. (1976). Obesity in young men after famine exposure in utero and early infancy. *N. Engl. J. Med.* 295, 349–353.
- Ricquier, D., and Bouillaud, F. (2000). Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance. *J. Physiol.* 529, 3–10.
- Schwartz, M.W., Woods, S.C., Porte, D., Jr., Seeley, R.J., and Baskin, D.G. (2000). Central nervous system control of food intake. *Nature* 404, 661–671.
- Stettler, N., Zemel, B.S., Kumanyika, S., and Stallings, V.A. (2002). Infant weight gain and childhood overweight status in a multicenter, cohort study. *Pediatrics* 109, 194–199.
- Tokuyama, K., and Himms-Hagen, J. (1986). Brown adipose tissue thermogenesis, torpor, and obesity of glutamate-treated mice. *Am. J. Physiol.* 251, E407–E415.
- Trayhurn, P., Thurlby, P.L., and James, W.P. (1977). Thermogenic defect in pre-obese *ob/ob* mice. *Nature* 266, 60–62.
- Wajchenberg, B.L. (2000). Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr. Rev.* 21, 697–738.
- Wells, J.C. (2003). The thrifty phenotype hypothesis: thrifty offspring or thrifty mother? *J. Theor. Biol.* 221, 143–161.
- Wilding, J.P. (2002). Neuropeptides and appetite control. *Diabet. Med.* 19, 619–627.
- Yamamoto, H., Lee, C.E., Marcus, J.N., Williams, T.D., Overton, J.M., Lopez, M.E., Hollenberg, A.N., Baggio, L., Saper, C.B., Drucker, D.J., and Elmquist, J.K. (2002). Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. *J. Clin. Invest.* 110, 43–52.

Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered Mice

Michio Nakanishi, Yoshihiko Saito, Ichiro Kishimoto, Masaki Harada, Koichiro Kuwahara, Nobuki Takahashi, Rika Kawakami, Yasuaki Nakagawa, Keiji Tanimoto, Shinji Yasuno, Satoru Usami, Yuhao Li, Yuichiro Adachi, Akiyoshi Fukamizu, David L. Garbers, Kazuwa Nakao

Abstract—Although plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are elevated early after myocardial infarction (MI), the significance is not fully understood. We therefore investigated the function of natriuretic peptides after induction of MI in knockout (KO) mice lacking the natriuretic peptide receptor guanylyl cyclase-A, the receptor for ANP and BNP. KO and wild-type (WT) mice were subjected to left coronary artery ligation and then followed up for 4 weeks. Irrespective of genotype, almost all deaths occurred within 1 week after induction of MI. KO mice showed significantly higher mortality because of a higher incidence of acute heart failure, which was associated with diminished water and sodium excretion and with higher cardiac levels of mRNAs encoding ANP, BNP, transforming growth factor- β 1, and type I collagen. By 4 weeks after infarction, left ventricular remodeling, including myocardial hypertrophy and fibrosis, and impairment of left ventricular systolic function were significantly more severe in KO than WT mice. Notably, the enhanced myocardial fibrosis seen in KO mice was virtually absent in infarcted double-KO mice, lacking guanylyl cyclase-A and angiotensin II type 1a receptors, although there was no improvement in survival and no attenuation of cardiac hypertrophy. Thus, guanylyl cyclase-A activation by endogenous cardiac natriuretic peptides protects against acute heart failure and attenuates chronic cardiac remodeling after MI. These beneficial effects are mediated partly through inhibition of the renin-angiotensin system (RAS), although RAS-independent protective actions of guanylyl cyclase-A are also suggested. (*Hypertension*. 2005;46:441-447.)

Key Words: receptors, angiotensin ■ coronary artery disease ■ hypertrophy ■ remodeling

Early reperfusion therapy and other recent advances in the treatment of acute myocardial infarction (MI) have substantially reduced mortality and cardiovascular morbidity among MI patients. However, the fact that acute heart failure and chronic left ventricular (LV) remodeling continue to be major determinants of clinical outcome after MI highlights the need for a better understanding of the pathophysiological mechanisms involved in those processes. In that regard, accumulating clinical and experimental evidence indicates that inhibition of the renin-angiotensin system (RAS) and the sympathetic nervous system improves postinfarct survival and mitigates LV remodeling and dysfunction.¹⁻⁴

Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are produced mainly in the atrial and ventricular myocardium, respectively, in response to volume expansion and pressure overload and counteract the effects of the sympathetic nervous system and RAS by promoting diuresis, natriuresis, and vasodilatation. The actions of both peptides

are mediated via the natriuretic peptide receptor guanylyl cyclase-A (GC-A), which is expressed in a variety of tissues, including kidneys, blood vessels, adrenal glands, and heart.⁵ Plasma levels of natriuretic peptides are elevated in congestive heart failure (CHF) and are frequently used to aid diagnosis of CHF, to assess prognosis, and to tailor therapy.⁶⁻⁹ In addition, exogenous administration of recombinant natriuretic peptides is now being used therapeutically to treat decompensated CHF.¹⁰

Plasma natriuretic peptide levels are also elevated early after MI;¹¹ in particular, the level of BNP has been shown to be a good predictor of LV systolic function and a prognostic indicator of long-term survival.¹² Although in a previous study, we suggested a role for GC-A in myocardial reperfusion injury and inflammation after ischemia-reperfusion,¹³ it remains unclear whether activation of the GC-A pathway by endogenous natriuretic peptides has a significant effect on survival or LV remodeling after MI. Therefore, to better

Received November 21, 2004; first decision December 9, 2004; revision accepted April 2, 2005.

From the Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine (M.N., I.K., M.H., K.K., N.T., R.K., Y.N., K.T., S.Y., S.U., Y.L., Y.A., K.N.), Japan; the First Department of Internal Medicine, Nara Medical University, Japan (Y.S.); the Center for Tsukuba Advanced Research Alliance, Institute of Applied Biochemistry, University of Tsukuba, Ibaraki, Japan (A.F.); and the Howard Hughes Medical Institute and Department of Pharmacology, University of Texas, Southwestern Medical Center at Dallas (D.L.G.).

Correspondence to Ichiro Kishimoto, MD, PhD, Department of Biochemistry, National Cardiovascular Center, Research Institute, 5-7-1 Fujishiro-dai, Suita City, Osaka 565-8565, Japan. E-mail kishimot@ri.nccvc.go.jp

© 2005 American Heart Association, Inc.

Hypertension is available at <http://www.hypertensionaha.org>

DOI: 10.1161/01.HYP.0000173420.31354.ef

Downloaded from hyper.ahajournals.org at KYOTO UNIV Igaku Toshokan on March 31, 2008

understand the function and significance of the increased natriuretic peptide levels seen after MI, we induced MI by occluding the left coronary artery (LCA) in GC-A knockout (KO) mice and their wild-type (WT) littermates and examined survival, LV structure, LV function, and cardiac gene expression.

Materials and Methods

Experimental Model

All experimental procedures were performed according to Kyoto University standards for animal care. Homozygous GC-A KO mice and their WT littermates were produced from crossing heterozygous mice as described previously,¹⁴ after which male mice were used for experimentation at 8 to 10 weeks of age.

Experimental MI

MI was produced by permanent ligation of the LCA, and sham-operated mice underwent the same operation except for the LCA ligation. Infarct size was calculated and expressed as the ratio of the infarcted circumference divided by total LV circumference, as described previously.¹⁵

Noninvasive Blood Pressure Measurements

Blood pressures and pulse rates were measured noninvasively in conscious mice using a computerized tail-cuff method (Softron Co, Ltd).

Urine Volume and Sodium Excretion

Animals were kept in individual metabolic cages from the day before surgery until 4 days after surgery. Urine was collected daily, and urine volume and sodium excretion were measured. Data were normalized to body weight (BW).

Cardiac Gene Expression

On day 3 after surgery, hearts were excised and the LVs were snap-frozen in liquid nitrogen. Total RNA was extracted from LVs, and expression of mRNAs was evaluated using quantitative RT-PCR analysis with gene-specific primers and probes in an ABI PRISM 7700 Sequence Detector (Applied Biosystems). Expression of the RNA in question was normalized to that of the corresponding GAPDH mRNA.

Echocardiography Examination

After anesthetizing mice by intraperitoneal administration of a mixture of ketamine (100 mg/kg) and xylazine (5 mg/kg), LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), percent fractional shortening (%FS), and LV posterior wall (PW) thickness were calculated before (baseline) and 4 weeks after induction of MI using an echocardiographic system (Toshiba Power Vision 8000) equipped with a 12-MHz imaging transducer.

Histological Analysis

To determine the degree of collagen fiber accumulation, we randomly selected 20 fields in 3 separate sections of formalin-fixed ventricles and calculated the ratio of the van Gieson-stained fibrotic area to the total myocardial area using image analysis software (KS400 image system; Zeiss).

Double-KO Mice Lacking GC-A and Angiotensin II Type 1a Receptors

Double-KO (DKO) mice lacking GC-A and angiotensin II type 1a (AT1a) receptors were generated from heterozygous mice after crossing of a single GC-A KO mouse and an AT1a KO mice.¹⁶

TABLE 1. Baseline Characteristics and Causes of Death After MI

Variables	WT (n=37)	GC-A KO (n=33)
Baseline characteristics		
Age (weeks)	9.6±0.2	9.2±0.1
BW (g)	25.3±0.4	25.7±0.5
Systolic BP (mm Hg)	98.9±1.5	128.3±1.5*
PR (bpm)	569.9±13.9	553.6±10.4
Causes of death, n (%)		
Heart failure	2 (5.4%)	18 (54.5%)*
LV rupture	8 (21.6%)	5 (15.2%)
Unknown	1 (2.7%)	1 (3.0%)

BP indicates blood pressure; PR, pulse rate.

Values are mean±SEM; *P<0.05 vs WT mice.

Hydralazine Administration

The blood pressures of GC-A KO mice were reduced to a level comparable to those seen in WT mice by orally administering hydralazine (50 mg/L of drinking water). Hydralazine was started 1 week before MI and continued until death, 4 weeks after MI.

Statistical Analysis

All data are expressed as means±SEM. Analysis of survival after MI was performed using the Kaplan–Meier method with the log-rank test. Data were analyzed by 1-factor ANOVA. If a statistically significant effect was found, a post hoc Newman–Keuls test was performed to isolate the differences between groups. Values of P<0.05 were considered significant.

Results

Survival After MI

The baseline characteristics of the KO and WT genotypes are shown in Table 1. There were no differences with respect to age, BW, or pulse rate between the 2 groups, although blood pressure was significantly higher in KO mice, as reported previously.^{14,17} Postoperative survival was monitored for 4 weeks (Figure 1). Irrespective of genotype, all deaths but 1 occurred within 1 week after induction of MI; 1 WT mouse




Figure 1. Kaplan–Meier analysis of survival after MI among WT (n=37) and GC-A KO mice (n=33). GC-A KO mice showed a significantly higher 4-week mortality rate than WT mice (P<0.0005).




Figure 2. Diuretic and natriuretic responses before and after MI. A, Urine volumes were measured 1 day before (pre-op) and on days 1 through 4 after induction of MI and normalized to the corresponding BWs; * $P < 0.05$ vs WT mice on each day. B and C, Total 4-day urine volume (B) and sodium excretion (C) were measured after induction of MI or sham operation and normalized to the corresponding BW. Values are means \pm SEM ($n = 12$ for WT mice; $n = 16$ for KO mice); * $P < 0.01$ vs sham in each strain; # $P < 0.05$ vs WT mice with MI.

died on day 14 after MI. Despite the fact that infarct sizes were similar in the 2 groups (KO $43.7 \pm 1.2\%$ versus WT $46.8 \pm 1.8\%$), the survival rate was significantly ($P < 0.0005$) lower among KO mice (27.3%; 9 of 33) than among WT mice (70.3%; 26 of 37).

Causes of Death

Based on postmortem findings, the causes of death were classified into 3 groups: heart failure, LV rupture, or unknown causes (Table 1). Heart failure was diagnosed from pulmonary congestion with increased lung weight, and LV rupture from the large amount of blood observed filling the chest cavity. The incidence of heart failure was significantly higher among KO mice than WT mice, although there were no significant differences between the 2 groups in the incidences of LV rupture or death by unknown causes.

Natriuretic and Diuretic Responses During Early Phase After MI

As shown in Figure 2A, there was no difference in urine volume between the 2 genotypes before surgery, and urine volume was markedly lower in both groups on day 1 after MI. Thereafter, volume increased gradually in both genotypes, but less so in KO mice. As a consequence, KO mice were producing significantly less urine than WT mice on days 3 and 4 after MI.

When we compared the renal responses of infarcted and sham-operated mice (Figure 2B and 2C), we found that the total 4-day urine volume and sodium excretion after the sham operation were similar for both genotypes. In contrast, over the course of 4 days after induction of MI, KO mice produced significantly less urine and excreted significantly less sodium than WT mice.

Cardiac Gene Expression During Early Phase After MI

On day 3 after sham operation, ventricular levels of ANP and BNP mRNA (Figure 3A and 3B) were higher in KO than WT hearts, probably because of basal LV hypertrophy in the former. In response to MI, both genotypes showed significant upregulation of ANP and BNP mRNA, but the postinfarction levels were still significantly higher in KO mice.

The cardiac expression of the mRNAs for transforming growth factor- $\beta 1$ (TGF- $\beta 1$) and type I collagen (Figure 3C and 3D) were similar in sham-operated WT and KO mice. Three days after MI, both genotypes showed significantly upregulated expression of TGF- $\beta 1$ and type I collagen mRNA, but the postinfarction levels were significantly higher in KO than WT mice.

Echocardiographic Findings During Late Phase After MI

To evaluate chronic LV remodeling, echocardiographic examination of the infarcted mice was performed before (baseline) and 4 weeks after induction of MI (Table 2). Baseline measurements showed KO mice to have greater LVEDD, LVESD, and PW thickness than WT mice, but %FS was similar, as reported previously.¹⁷ Four weeks after MI, both genotypes showed significant chamber enlargement and impaired LV contractility. Although no significant difference in the absolute increase in LVEDD was observed, the absolute decrease in %FS and the absolute increases in LVESD and PW thickness were significantly greater in KO than in WT mice.

Changes in Heart Weights During Late Phase After MI

Among sham-operated animals, KO mice had larger heart weight-to-BW (HW/BW) ratios, which reflected basal myo-




Figure 3. Relative levels of expression of ANP (A), BNP (B), TGF- β 1 (C), and type I collagen (D) mRNA normalized to the corresponding GAPDH mRNA levels measured by quantitative RT-PCR in sham-operated and infarcted hearts 3 days after surgery. Mean mRNA levels in sham-operated WT hearts were assigned a value of 1.0. Values are means \pm SEM (n=7 to 10); * P <0.05 vs WT mice for each operation; # P <0.05 vs sham in each strain.

cardial hypertrophy (WT 5.44 ± 0.14 mg/g versus KO 7.94 ± 0.20 mg/g; P <0.001). Four weeks after MI, the HW/BW ratios were higher than in sham-operated mice, irrespective of genotype, but the effect was more pronounced in KO (Sham 7.94 ± 0.20 mg/g versus MI 10.12 ± 0.20 mg/g; 27% increase; P <0.0001) than WT (Sham 5.44 ± 0.14 mg/g versus MI 6.29 ± 0.14 mg/g; 16% increase; P <0.005) mice.

Myocardial Fibrosis During Late Phase After MI

As shown in Figure 4A, sections of ventricle from sham-operated KO mice showed significantly (P <0.01) more myocardial collagen accumulation than those from WT mice. Four weeks after MI, the collagen volume fraction in the noninfarcted septa was significantly increased in KO mice (P <0.0001) but not in WT mice (P =0.6). This marked difference in the degree

of interstitial fibrosis in the noninfarcted septa from KO and WT mice can be seen in Figure 4B.

Effects of Genetic Disruption of AT1a Receptors in KO Mice

In an additional experiment, we induced MI in 8- to 10-week-old male DKO mice lacking GC-A and AT1a receptors. Although basal systolic blood pressures were significantly lower in DKO than KO mice (DKO 105.8 ± 2.6 mm Hg; P <0.0001 versus KO mice), the high early mortality rate seen in the latter was not significantly improved in the former (Figure 5); and, as in KO mice, most of the deaths were attributable to acute heart failure (68.2%). Four weeks after MI, HW/BW ratios in DKO mice were 26% higher than in sham-operated animals (Sham 7.06 ± 0.20 mg/g versus MI 8.88 ± 0.42 mg/g; P <0.001), which is also similar to the response seen in KO mice. In contrast, there was no significant difference in the collagen volume fraction in the noninfarcted septa from infarcted and sham-operated DKO hearts (Figure 4A); indeed, the marked interstitial fibrosis seen in the noninfarcted septa from KO hearts was virtually absent in DKO hearts (Figure 4B).

Effects of Hydralazine Administration in KO Mice

To evaluate the involvement of blood pressure difference between WT and KO mice, we orally administered hydralazine to KO mice from 1 week before MI until 4 weeks after MI. Although systolic blood pressure was significantly reduced in hydralazine-treated KO mice (103.6 ± 1.2 mm Hg; P <0.0001 versus nontreated KO mice), the high early mortality rate was not significantly improved (Figure 5), and histological analysis showed there to be no significant attenuation of the interstitial fibrosis in the noninfarcted septum 4 weeks after MI (Figure 4).

TABLE 2. Baseline, Week 4, and Absolute Changes From Baseline to Week 4 After MI in Echocardiographic Measurements

Parameters	WT (n=13)		GC-A KO (n=11)	
	Baseline	Week 4	Baseline	Week 4
Measurements				
LVEDD (mm)	4.55 \pm 0.08	5.76 \pm 0.08	5.11 \pm 0.10*	6.26 \pm 0.14*
LVESD (mm)	3.31 \pm 0.06	4.54 \pm 0.09	3.69 \pm 0.09*	5.28 \pm 0.12*
PWth (mm)	0.63 \pm 0.02	0.65 \pm 0.03	0.85 \pm 0.05*	1.02 \pm 0.04*
%FS (%)	27.4 \pm 0.3	21.5 \pm 1.0	27.5 \pm 0.6	15.6 \pm 0.9*
Absolute change from baseline to week 4 after MI				
Δ LVEDD (mm)		1.22 \pm 0.06		1.16 \pm 0.08
Δ LVESD (mm)		1.24 \pm 0.09		1.59 \pm 0.09*
Δ PWth (mm)		0.02 \pm 0.03		0.17 \pm 0.05*
Δ %FS (%)		-5.9 \pm 1.1		-11.9 \pm 1.1*

PWth indicates PW thickness.

Values are mean \pm SEM; * P <0.05 vs WT mice.




Figure 4. A. Evaluation of collagen volume in sham-operated hearts and noninfarcted regions of infarcted hearts from WT, GC-A KO, DKO, and hydralazine-treated GC-A KO mice 4 weeks after surgery. Values are means \pm SEM ($n=6$ to 9); * $P<0.05$ vs WT mice for each operation; # $P<0.05$ vs sham-operated KO mice; † $P<0.0001$ vs KO mice with MI. B. Representative van Gieson-stained sections showing noninfarcted regions in infarcted hearts from WT, GC-A KO (KO), DKO, and hydralazine-treated GC-A KO (h-KO) mice. Images show the interstitial collagen deposition (red staining) 4 weeks after induction of MI. Bars=200 μ m.

Discussion

Although plasma ANP and BNP levels are known to be elevated early after MI,¹¹ their function in that context has been unclear. The present study shows that disrupting GC-A in mice results in a higher incidence of acute heart failure leading to increased early mortality and, later, in exaggerated LV dysfunction and remodeling. Thus, natriuretic peptides appear to exert beneficial effects during the early and late stages after MI.

During the 4-week study period, almost all deaths among both genotypes occurred within the first week after MI and were the result of heart failure or LV rupture. This survival pattern suggests that the rapid worsening of hemodynamics and mechanical stress after MI is, for the most part, compensated by the end of 1 week and stable for ≥ 3 weeks thereafter. In contrast to our previous study performed using




Figure 5. Kaplan-Meier analysis of survival after MI among GC-A KO ($n=33$), DKO mice ($n=33$), and hydralazine-treated GC-A KO (hydralazine-KO; $n=31$) mice. DKO mice and hydralazine-treated GC-A KO showed no significant improvement in 4-week survival over GC-A KO mice.

an ischemia-reperfusion model,¹³ infarct sizes were similar among the 2 genotypes, which is likely because permanent coronary occlusion changes the entire area at risk into infarction. This enabled us to compare the mortality rates and chronic LV remodeling resulting from similar insults in the 2 groups. Despite similar infarct sizes, the 1-week mortality rate was markedly higher in KO than WT mice. Postmortem findings indicate that the higher 1-week mortality rate in KO mice is attributable to a higher incidence of acute heart failure, which is consistent with the higher levels of cardiac expression of ANP and BNP mRNA observed in KO mice early after MI. Together, these results indicate that KO mice have a diminished capacity to compensate for acute heart failure after MI.

KO mice excreted less water and sodium than WT mice after MI, despite similar excretion during the early phase after the sham operation. Previous studies have shown that the infusion of 0.9% NaCl containing 4% albumin (isooncotic solution) results in impaired diuretic and natriuretic responses in GC-A KO mice, whereas the infusion of physiological saline (isotonic solution) leads to normal renal responses.¹⁸ Because CHF could cause isooncotic volume expansion, the impaired renal response after MI in GC-A KO mice is consistent with the idea that GC-A plays an important role in diuresis and natriuresis under such pathological conditions as heart failure, although it is not essential under basal conditions.

Natriuretic peptides are known to act as negative regulators of renin-angiotensin-aldosterone system. Indeed, we showed previously that cardiac responsiveness to angiotensin II was significantly enhanced in the absence of GC-A,¹⁶ and a previous study reported that natriuretic peptides reduced gene expression of aldosterone synthase in cultured neonatal rat cardiocytes.¹⁹ In addition, there is clinical and experimental evidence that suppression of RAS activity reduces postinfarction mortality.^{1,3,4} Therefore, we hypothesized that the higher mortality in KO mice was associated with greater activation

of RAS resulting from the lack of GC-A-mediated inhibition. To test that hypothesis, we compared postinfarction survival rates in GC-A KO and DKO mice, which lack GC-A and AT1a receptors. However, surprisingly, the 4-week survival rate for DKO mice was no better than that for KO mice, despite their significantly lower basal blood pressures (to a level similar to WT mice), and again most deaths were attributable to acute heart failure. Apparently, the protective role against heart failure played by GC-A early after MI is not mediated by reduction of blood pressure or inhibition of RAS.

GC-A attenuates chronic cardiac remodeling in a pressure-overload model (transverse aortic constriction)²⁰ and in a chronic hypoxia model.²¹ The present study demonstrates that GC-A also attenuates cardiac hypertrophy and fibrosis and impaired LV contractility during the chronic phase after MI. Because previous studies have shown that inhibition of RAS diminishes LV remodeling after MI,^{1,4} we were also interested in comparing LV remodeling in DKO and GC-A KO mice. Notably, the patterns of development of myocardial fibrosis and cardiac hypertrophy differed in the 2 genotypes (ie, the augmented fibrotic response was virtually abolished in DKO mice, although there was no attenuation of the enhanced hypertrophic response). Because previous reports have shown that natriuretic peptides exert a direct local antihypertrophic effect in vivo^{20,22} and in vitro,²³ it is suggested that a direct action mediated via GC-A expressed on cardiac myocytes may be important after MI. We also evaluated the fibrotic response in hydralazine-treated GC-A KO mice, for which blood pressures were similar to those of DKO mice. However, hydralazine did not significantly affect the fibrotic response in KO mice, indicating the antifibrotic effect of GC-A is mediated mainly through inhibition of RAS, including aldosterone, not through reduction of blood pressure.

A recent clinical trial demonstrated that intravenous infusion of nesiritide (synthetic human BNP) improves the hemodynamic function and clinical status of patients with decompensated CHF.¹⁰ Although patients with recent MIs were excluded from that trial, the present study suggests that infusion of BNP could also have beneficial effects in patients with heart failure early after MI. In addition, a study of 60 Japanese patients with anterior MI showed that infusion of carperitide (recombinant ANP) suppressed LV remodeling evaluated 1 month after MI better than nitroglycerin did.²⁴ Certainly, the lack of an oral form makes the use of natriuretic peptides somewhat impractical for long-term treatment; nevertheless, therapeutic strategies aimed at increasing levels of endogenous natriuretic peptides might be beneficial for patients after MI and deserve further investigation.

Functional deletion of the 5'-flanking region of the GC-A gene reduces transcriptional activity and is associated with essential hypertension and LV hypertrophy.²⁵ This means that individuals with congenital or acquired GC-A deficiencies would likely be at higher risk of death and exaggerated LV remodeling after MI. Perhaps genotyping the GC-A locus would be a useful approach to identifying these patients, thereby enabling early preventative measures to be taken.

Perspectives

Activation of GC-A by endogenous natriuretic peptides after MI prevents acute heart failure and attenuates chronic LV remodeling. Although these beneficial effects are mediated partly through inhibition of RAS activity, RAS-independent protective actions of GC-A are also suggested. The results of this study are suggestive of the potential for using exogenous ANP or BNP to improve short- and long-term outcomes among MI patients.

Acknowledgments

This work was supported by research grants from the Japanese Ministry of Education, Science, and Culture; the Japanese Ministry of Health and Welfare; the Japanese Society for the Promotion of Science Research for the Future program; and the KANAE Foundation for Life and Socio-Medical Science. GC-A KO mice were originally generated at the University of Texas, Southwestern Medical Center in Dallas and the Howard Hughes Medical Institute. We thank Kana Okamura and Komaki Okazaki for their excellent secretarial work and Mikako Inoue for her technical help.

References

- Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. *Lancet*. 1994;343:1115-1122.
- Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction the CAPRICORN randomized trial. *Lancet*. 2001;357:1385-1390.
- Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Werf FV, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003;349:1893-1906.
- Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. *Circulation*. 1999;100:2093-2099.
- Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. *J Hypertens*. 1992;10:1111-1114.
- Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Imura H. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. *Circulation*. 1993;87:464-469.
- Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*. 2002;347:161-167.
- Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, Moser P, Bojic A, Hartter E, Pacher R. Prognostic evaluation of neurohormonal plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. *J Am Coll Cardiol*. 2001;38:436-442.
- Troughton RW, Frampton CM, Tandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. *Lancet*. 2000;355:1126-1130.
- Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. *N Engl J Med*. 2000;343:246-253.
- Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura M, Mukoyama M, Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. *Circulation*. 1993;88:82-91.

12. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilson DW, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptides as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. *Circulation*. 1996;93:1963–1969.
13. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, Nakao K. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF- κ B activation and alleviates myocardial ischemia/reperfusion injury. *J Clin Invest*. 2001;108:203–213.
14. Lopez MJ, Wong SKF, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DJ, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. *Nature*. 1995;378:65–68.
15. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. *Circ Res*. 1979;44:503–512.
16. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K. Guanylyl cyclase-A inhibits angiotensin II type 1a receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. *Circulation*. 2002;106:1722–1728.
17. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. *Proc Natl Acad Sci U S A*. 1997;94:14730–14735.
18. Kishimoto I, Dubois SK, Garbers DL. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. *Proc Natl Acad Sci U S A*. 1996;93:6215–6219.
19. Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Yamamuro M, Harada M, Saito Y, Nakao K, Kurihara H, Yasue H, Ogawa H. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. *Circulation*. 2003;107:807–810.
20. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. *J Clin Invest*. 2001;107:975–984.
21. Klinger JR, Warburton RR, Pietras L, Oliver P, Fox J, Smithies O, Hill NS. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. *Am J Physiol Heart Circ Physiol*. 2002;282:H58–H65.
22. Holtwick R, Eickels MV, Skryabin BV, Baba HA, Bubikat A, Begrow F, Schneider MD, Garbers DL, Kuhn M. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. *J Clin Invest*. 2003;111:1399–1407.
23. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kanagawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. *Hypertension*. 2000;35:19–24.
24. Hayashi M, Tsutomoto T, Wada A, Maeda A, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. *J Am Coll Cardiol*. 2001;37:1820–1826.
25. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K. Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. *Circ Res*. 2000;86:841–845.